Holen Sie sich die Stockscreener-App
1.04
0.97%
0.01
Handel nachbörslich:
1.04
Schlusskurs vom Vortag:
$1.03
Offen:
$1.06
24-Stunden-Volumen:
7.91M
Relative Volume:
2.07
Marktkapitalisierung:
$227.48M
Einnahmen:
$95,000
Nettoeinkommen (Verlust:
$-327.27M
KGV:
-0.4906
EPS:
-2.12
Netto-Cashflow:
$-239.25M
1W Leistung:
-1.89%
1M Leistung:
-18.75%
6M Leistung:
-26.24%
1J Leistung:
-55.74%
1-Tages-Spanne:
$1.03
$1.08
1-Wochen-Bereich:
$0.9842
$1.105
52-Wochen-Spanne:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALLO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.04 | 225.29M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-28 | Bestätigt | B. Riley Securities | Buy |
| 2021-10-20 | Eingeleitet | Cowen | Outperform |
| 2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-10-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Fortgesetzt | Jefferies | Buy |
| 2021-05-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-26 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-11-24 | Eingeleitet | BofA Securities | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
| 2020-04-13 | Eingeleitet | SunTrust | Buy |
| 2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-24 | Eingeleitet | Berenberg | Hold |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-23 | Eingeleitet | Stifel | Hold |
| 2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts - Investing.com Nigeria
Allogene Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allogene Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle
Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Will Allogene Therapeutics Inc. benefit from macro trendsMulti-Year Investment Performance Summary Report - Newser
Allogene Therapeutics Inc. stock trend forecastMarket Stability and Long-Term Growth Outlook - Newser
Volume spikes in Allogene Therapeutics Inc. stock – what they meanDaily Trade Monitor with Pattern Alerts - Newser
Can trapped investors hope for a rebound in Allogene Therapeutics Inc.Smart Trend Analysis With Buy Point Cues - Newser
Allogene Therapeutics shares rise 2.86% after-hours following Sumitomo Pharma's submission for Parkinson's disease treatment. - AInvest
Is Allogene Therapeutics Inc. meeting your algorithmic filter criteriaPre-Market Stock Movement Summary and Review - Newser
Follicular Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Bio - Barchart.com
Allogene Therapeutics Schedules Conference Call and Webcast to Discuss Q2 2025 Financial Results on August 13 - Quiver Quantitative
Allogene Therapeutics announces Q2 2025 financial results, conference call on August 13. - AInvest
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - Stock Titan
How to integrate Allogene Therapeutics Inc. into portfolio analysis toolsFree Breakout Entry Signal Confirmation Tool - Newser
Allogene Therapeutics shares fall 1.36% intraday after Sumitomo Pharma and RACTHERA submit application for Parkinson's disease treatment. - AInvest
What makes Allogene Therapeutics Inc. stock price move sharplyEquity Signal Recap With Long-Term Summary - Newser
JMP Securities Reiterates Market Perform Rating for Allogene Therapeutics Inc. - AInvest
Allogene Therapeutics Maintains Buy Rating Amid Strategic Adjustments and Technological Advancements - AInvest
Patient Dies After Receiving Monoclonal Antibody Lymphodepletion Regimen in LBCL Trial for Allogene’s Cema-Cel - CGTLive®
Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death - insights.citeline.com
Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment - Investing.com Canada
Allogene stock continues ALPHA3 trial with standard FC regimen after safety event - Investing.com Canada
Allogene Scraps Immunosuppressive Antibody After Patient Death in Lymphoma Trial - BioSpace
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Benzinga
Patient death in Allogene trial - The Pharma Letter
What is Allogene Therapeutics Inc. company’s growth strategyBuild wealth steadily with proven investment strategies - Jammu Links News
What are the technical indicators suggesting about Allogene Therapeutics Inc.High-yield growth strategies - Jammu Links News
When is Allogene Therapeutics Inc. stock expected to show significant growthInvest confidently with market-leading analysis - Jammu Links News
How does Allogene Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - Jammu Links News
Is it the right time to buy Allogene Therapeutics Inc. stockJaw-dropping returns - Jammu Links News
Is Allogene Therapeutics Inc. stock overvalued or undervaluedMaximize returns with disciplined investment techniques - Jammu Links News
What drives Allogene Therapeutics Inc. stock priceStrong return on assets - Jammu Links News
What are Allogene Therapeutics Inc. company’s key revenue driversUnstoppable profit momentum - Jammu Links News
How many analysts rate Allogene Therapeutics Inc. as a “Buy”Access daily stock market expert updates - Jammu Links News
What is the dividend policy of Allogene Therapeutics Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News
What are the latest earnings results for Allogene Therapeutics Inc.Jaw-dropping returns - Jammu Links News
Allogene Therapeutics updates ALPHA3 trial protocol following safety event By Investing.com - Investing.com Australia
How volatile is Allogene Therapeutics Inc. stock compared to the marketBeginner Investor Report With Low Risk - Jammu Links News
Allogene Therapeutics Faces Market Volatility Amid Financial Challenges - StocksToTrade
Allogene Resets Clinical Course After Patient Death In Lymphoma StudyAllogene Therapeutics (NASDAQ:ALLO) - Benzinga
Regeneron cancer bispecific rejected again; Allogene discloses trial death - BioPharma Dive
Allogene Therapeutics updates ALPHA3 trial protocol following safety event - Investing.com
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event - TipRanks
RENT Form 144: Insider plans to sell 262 shares worth $1.49k | ALLO SEC FilingForm 8-K - Stock Titan
Allogene Therapeutics Announces Selection of Standard FC Lymphodepletion Regimen in ALPHA3 Study Following Consultation with FDA and Safety Board - Quiver Quantitative
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - The Manila Times
Allogene says lymphodepletion drug caused patient death, changes CAR-T study design - Endpoints News
Allogene Therapeutics shares rise 2.33% premarket after Robbins LLP class action filing. - AInvest
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):